Spago Nanomedical AB (publ)

DB:7UX Stock Report

Market Cap: €5.5m

Spago Nanomedical Past Earnings Performance

Past criteria checks 0/6

Spago Nanomedical's earnings have been declining at an average annual rate of -24.6%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been declining at an average rate of 35% per year.

Key information

-24.6%

Earnings growth rate

8.9%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate-35.0%
Return on equity-102.2%
Net Margin-711.9%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown
Beta

How Spago Nanomedical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:7UX Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 236-42240
30 Sep 239-41240
30 Jun 239-42250
31 Mar 238-44250
31 Dec 226-39250
30 Sep 226-39250
30 Jun 226-41240
31 Mar 226-43240
31 Dec 216-39240
30 Sep 217-32230
30 Jun 217-27220
31 Mar 217-20200
31 Dec 207-19190
30 Sep 207-20210
30 Jun 2013-21220
31 Mar 2016-21230
31 Dec 1919-20230
30 Sep 1925-18220
30 Jun 1925-15210
31 Mar 1927-13210
31 Dec 1830-11200
30 Sep 1830-11200
30 Jun 1827-10190
31 Mar 1823-10190
31 Dec 1718-9180
30 Sep 1713-8160
30 Jun 1712-8150
31 Mar 1711-7150
31 Dec 1611-8150
30 Sep 169-7140
30 Jun 168-7130
31 Mar 168-7130
31 Dec 158-7120
30 Sep 157-8130
30 Jun 157-7120
31 Mar 157-7120
31 Dec 148-6110
30 Sep 147-7110
30 Jun 149-7110
31 Mar 148-5100
31 Dec 138-5100
30 Sep 1310-4100
30 Jun 139-4100
31 Mar 139-590

Quality Earnings: 7UX is currently unprofitable.

Growing Profit Margin: 7UX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 7UX is unprofitable, and losses have increased over the past 5 years at a rate of 24.6% per year.

Accelerating Growth: Unable to compare 7UX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 7UX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.2%).


Return on Equity

High ROE: 7UX has a negative Return on Equity (-102.19%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.